Alembic Pharma gets final USFDA approval for Lacosamide tablet Lacosamide tablet
indicated for the treatment of partial-onset seizures in patients of four years of age and older. izures in patients of four years of age and older. Alembic Pharmaceuticals Ltd gets final approval from the USFDA for its generic version of Lacosamide tablet, indicated for the treatment of partial-onset seizures in patients of four years of age and older. The approval by the US health regulator is for the abbreviated new drug application (ANDA) for Lacosamide tablets of strengths 50 mg, 100 mg, 150 mg, and 200 mg, the company said in a statement. The approved ANDA is therapeutically equivalent to the reference listed drug product Vimpat Tablets -- 50 mg, 100 mg, 150 mg, and 200 mg-of UCB Inc, it
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
